• IMA sites
  • IMAJ services
  • IMA journals
  • Follow us
  • Alternate Text Alternate Text
עמוד בית
Fri, 22.11.24

Search results


August 2009
M. García-Carrasco, C. Mendoza-Pinto, R.O. Escárcega, M. Jiménez-Hernández, I. Etchegaray Morales, P. Munguía Realpozo, J. Rebollo-Vázquez, E. Soto-Vega, M. Delezé and R. Cervera

In recent years the survival of patients with systemic lupus erythematosus has increased markedly. Consequently, long-term complications, such as osteoporosis, are currently of paramount importance. SLE[1] is known to increase the risk of bone fractures, and numerous studies have found that SLE patients have osteoporosis. Of the various risk factors associated with osteoporosis in SLE, disease duration, the use of corticosteroids and chronic disease-related damage are consistently reported, with differences between studies probably due to the different populations studied. The role of chronic inflammation in osteoporosis is also important. On the other hand, little attention has been paid to osteoporotic fractures, especially of the vertebra, which are associated with reduced quality of life, increased mortality rates and increased risk of new vertebral and non-vertebral fractures in the general population.






[1] SLE = systemic lupus erythematosus



 
August 2007
M. Garcia-Carrasco, R.O. Escarcega, C. Mendoza-Pinto, A. Zamora-Ustaran, I. Etchegaray-Morales, J. Rojas-Rodriguez, L.E. Escobar-Linares and R. Cervera
Legal Disclaimer: The information contained in this website is provided for informational purposes only, and should not be construed as legal or medical advice on any matter.
The IMA is not responsible for and expressly disclaims liability for damages of any kind arising from the use of or reliance on information contained within the site.
© All rights to information on this site are reserved and are the property of the Israeli Medical Association. Privacy policy

2 Twin Towers, 35 Jabotinsky, POB 4292, Ramat Gan 5251108 Israel